U.S. markets close in 5 hours 19 minutes

Tryp Therapeutics Inc. (TRYPF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0638+0.0138 (+27.60%)
As of 09:48AM EST. Market open.

Tryp Therapeutics Inc.

1665 Ellis Street
Suite 301
Kelowna, BC V1Y 2B3
833 811 8797

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. James P. Gilligan MSIB, Ph.D.Interim CEO, Pres & Chief Scientific Officer137.49kN/A1952
Dr. James S. Kuo M.B.A., M.D.Co-Founder & Director69.44kN/A1965
Mr. Jim O'NeillChief Financial OfficerN/AN/AN/A
Mr. Thomas D'Orazio B.Sc., M.B.A.Chief Operating OfficerN/AN/AN/A
Mr. Sidney Taubenfeld R.PhChief Operating OfficerN/AN/AN/A
Ms. Joy WillisDirector of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 and TRP-8803 for fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. The company has an agreement with the Calvert Labs to design and execute exploratory studies related to psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was incorporated in 2019 and is based in Kelowna, Canada.

Corporate Governance

Tryp Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.